Table 1:

FDA approved ICI therapy and their current indications. Adapted from Wang et al. [73].

Drug	Target	Date of approval by the FDA	Indications
Ipilimumab	CTLA-4	2011	Melanoma, renal cell carcinoma, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, malignant pleural mesothelioma, esophageal cancer
Nivolumab	PD-1	2014	Melanoma, non-small cell lung cancer, malignant pleural mesothelioma, renal cell carcinoma, classical Hodgkin lymphoma, squamous cell carcinoma of the head and neck, urothelial carcinoma, colorectal cancer, hepatocellular carcinoma, esophageal cancer, gastric cancer, gastroesophageal junction cancer, esophageal adenocarcinoma
Pembrolizumab	PD-1	2014	Melanoma, non⁠-small cell lung cancer, head and neck squamous cell carcinoma, classical Hodgkin lymphoma, primary mediastinal large B cell lymphoma, urothelial carcinoma, non-muscle invasive bladder cancer, colorectal cancer, gastric cancer, esophageal cancer, cervical cancer, hepatocellular carcinoma, Merkel cell carcinoma, renal cell carcinoma, endometrial carcinoma, cutaneous squamous cell carcinoma, triple-negative breast cancer
Atezolizumab	PD-L1	2016	Non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, alveolar soft part sarcoma
Durvalumab	PD-L1	2017	Non-small cell lung cancer, small cell lung cancer, biliary tract cancer, hepatocellular carcinoma
Avelumab	PD-L1	2017	Merkel cell carcinoma, urothelial carcinoma, renal cell carcinoma
Cemiplimab	PD-1	2019	Cutaneous squamous cell carcinoma, basal cell carcinoma, non-small cell lung cancer
Dostarlimab	PD-1	2021	Endometrial cancer
Relatlimab	LAG-3	2022	Melanoma